Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Mead Johnson Nutrition CO (MJN): Is This Company’s Cash Cow Drying Up?

Page 1 of 2

Shares of Mead Johnson Nutrition CO (NYSE:MJN) plunged recently, after Chinese regulators stated that they were investigating claims that foreign companies were intentionally overcharging for infant formula to capitalize on fears of domestic contamination of dairy products. Foreign milk-powder companies have raised their prices 30% since 2008, according to China’s state-controlled People’s Daily newspaper.

Mead Johnson Nutrition CO (NYSE:MJN)

Will this investigation derail the growth of Mead Johnson Nutrition CO (NYSE:MJN) and its industry peers in China, which has been considered a fertile growth market for infant formula, or has the company’s 8% slide on July 3 presented a buying opportunity for long-term investors?

The melamine scandal

In 2008, at least six infants died from consuming melaminetainted milk powder from domestic formula producers in China. Melamine, along with cyanuric acid, ammeline and ammelide, can be used to inflate the apparent protein content of products, allowing cheaper, dangerous products to be sold as more expensive ones. Although melamine is not believed to be extremely toxic by itself, it can cause kidney failure and death when combined with cyanuric acid. This protein export contamination first reared its ugly head in the 2007 pet food scandal, before spreading to the domestic infant formula market.

This public distrust of domestic milk-formula brands, exacerbated by the government’s slow response to the crisis, led to a surge in demand for foreign brands from Mead Johnson Nutrition CO (NYSE:MJN), Abbott Laboratories (NYSE:ABT), Danone and Nestle SA. As a result, foreign formula brands now account for nearly half of China’s milk-formula market, which has led to charges of price collusion between the largest companies.

Leading domestic milk-formula producers Biostime, Beingmate and Yili are also being investigated by government regulators, indicating that both foreign and domestic brands could be forced to lower their prices significantly.

Mead Johnson’s milk business could spoil

Mead Johnson Nutrition CO (NYSE:MJN) has the most to lose compared to its industry peers. Mead Johnson controlled 14% of China’s 77.9 billion yuan ($12.6 billion) milk-formula market in 2012, according to research firm Euromonitor International, followed by domestic producer Hangzhou Beingmate Group at 10% and Danone at 9.2%. Mead Johnson’s business in China accounts for approximately 30% of its annual revenue. By comparison, Abbott Laboratories (NYSE:ABT) only generates 5% of its top line from infant formula sales in China.

Nestle, which acquired infant-formula producer Vevey from Pfizer Inc. (NYSE:PFE) in 2012, has a far more diversified business than Mead Johnson Nutrition CO (NYSE:MJN) and Danone, with only a marginal market share of the Chinese infant formula market. Therefore, Nestle has readily complied with the Chinese government, initially slashing its prices by 6% to 20% last April, and promising an average price reduction of 11% later this year.

Danone, which has a lot more to lose than Nestle, stated its Dumex formula segment was preparing to reduce prices. Last quarter, Danone’s baby food sales surged 17% year-on-year due to infant-formula hoarding. In addition, demand for Danone’s bottled water brands, including Evian, remained robust as well, due to concerns about the quality of the water supply in urban areas.

Mead Johnson Nutrition CO (NYSE:MJN), which stands to lose the most in revenue, hasn’t released an official statement about upcoming price reductions yet, but it stated that it was “cooperating fully” with Chinese regulators regarding the issue.

Consolidating the milk-formula industry

However, China has another publicly stated motive for targeting of foreign formula makers. Last month, the Ministry of Industry and Information stated that it was in the process of consolidating its milk-formula industry with the intention of creating ten safe and strong domestic brands to restore the faith of concerned consumers.

The Chinese government’s efforts to promote domestic dairy products have caused shares of Mengniu Dairy, the country’s largest dairy producer, to surge. Mengniu has rallied more than 30% over the past three months as a result – a stark contrast to the rest of the lagging Chinese markets in Shanghai and Hong Kong. COFCO, China’s state-owned agricultural and food industry supplier, owns a 19% stake in Mengniu, which will be the direct beneficiary of a widespread market consolidation.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!